2024
Human Factors Contributing to Infection Prevention in Outpatient Hemodialysis Centers: A Mixed Methods Study
Parker S, Jesso M, Wolf L, Leigh K, Booth S, Gualandi N, Garrick R, Kliger A, Patel P. Human Factors Contributing to Infection Prevention in Outpatient Hemodialysis Centers: A Mixed Methods Study. American Journal Of Kidney Diseases 2024, 84: 18-27. PMID: 38447708, PMCID: PMC11193600, DOI: 10.1053/j.ajkd.2023.12.024.Peer-Reviewed Original ResearchInfection preventionMultidisciplinary teamDialysis facilitiesMixed methods studyOutpatient hemodialysis centersOutpatient dialysis facilitiesOutpatient dialysis settingInfection prevention effortsOutpatient dialysis centersDialysis centersOutpatient careStaff conversationsMethods studyPrevention effortsStaff encounterDialysis settingAxial codingPrevention barriersAbstractText Label="RATIONALEMacroergonomic approachWork system designHemodialysis centersPreventionSample sizeQuantitative data
2023
Approaches to Maximize Safety for Patients with Kidney Diseases after the End of COVID-19 Public Health Emergency
Silberzweig J, Kliger A, White D, Stark S, Kumar V. Approaches to Maximize Safety for Patients with Kidney Diseases after the End of COVID-19 Public Health Emergency. Clinical Journal Of The American Society Of Nephrology 2023, 19: 263-265. PMID: 37642955, PMCID: PMC10861095, DOI: 10.2215/cjn.0000000000000303.Peer-Reviewed Original ResearchEffects of Spironolactone on Arrhythmias in Hemodialysis Patients: Secondary Results of the SPin-D Randomized Controlled Trial
Mc Causland F, Hsu J, Himmelfarb J, Ikizler T, Raj D, Mehrotra R, Waikar S, Kimmel P, Kliger A, Dember L, Charytan D, Kliger A, Charytan D, Mc Causland F, Robinson E, Waikar S, Williams M, Weiner D, Aurien-Blajeni E, Cinelli M, Nizam T, Rim S, Seok P, Smith C, Curtis J, Raj D, Regunathan-Shenk R, Sharma S, Ramezani A, Andrews S, Dumadag M, Franco C, Wing M, Himmelfarb J, Mehrotra R, Anderson L, Linke L, Manahan L, Ikizler T, Hung A, Cavanaugh K, Booker C, Brannon B, Clagett A, Ellis C, Dember L, Landis J, Anderson A, Hsu J, Cifelli D, Ballard S, Durborow M, Howard T, Kuzla N, Nessel L, Tierney A, Skali H, Solomon S, Rad A, Di Carli M, Gaber M, Foster C, Kimmel P, Kusek J. Effects of Spironolactone on Arrhythmias in Hemodialysis Patients: Secondary Results of the SPin-D Randomized Controlled Trial. Kidney360 2023, 4: e486-e495. PMID: 36763641, PMCID: PMC10278797, DOI: 10.34067/kid.0000000000000067.Peer-Reviewed Original ResearchConceptsEffect of spironolactoneFrequency of bradycardiaMaintenance hemodialysisFollow-upPost hoc analysisConduction blockArrhythmic eventsCardiovascular eventsMaintenance HDSudden deathHoc analysisIncidence of cardiovascular eventsAssociation of spironolactoneDose of spironolactoneRisk of cardiovascular eventsDouble-blind trialProportion of patientsPatients treated with maintenance HDRandomized controlled trialsGeneralized estimating equation modelsSpironolactone groupPlacebo-controlledSpironolactone treatmentBradycardic eventsAge of participantsSome Lessons Learned for Kidney Failure Patients in the COVID-19 Pandemic
Kliger A, Silberzweig J, McNamara E, Stark S. Some Lessons Learned for Kidney Failure Patients in the COVID-19 Pandemic. Clinical Journal Of The American Society Of Nephrology 2023, 18: 946-948. PMID: 36723343, PMCID: PMC10356111, DOI: 10.2215/cjn.0000000000000090.Peer-Reviewed Original ResearchKidney Transplant Practice in Pandemic Times
Kumar V, Leigh K, Kliger A, Roberts G, Mohan S, Leca N, Sawinski D, Josephson M, Mannon R, Lentine K. Kidney Transplant Practice in Pandemic Times. Clinical Journal Of The American Society Of Nephrology 2023, 18: 961-964. PMID: 36795033, PMCID: PMC10356143, DOI: 10.2215/cjn.0000000000000092.Peer-Reviewed Original Research54 COVID-19 and Dialysis Patients
Silberzweig J, Kliger A. 54 COVID-19 and Dialysis Patients. 2023, 491-496. DOI: 10.1016/b978-0-323-79135-9.00054-9.ChaptersDialysis therapyIntermittent renal replacement therapyCOVID-19Continuous dialysis therapyAcute kidney injuryChronic kidney diseaseRenal replacement therapyAcute peritoneal dialysisAssociated risk factorsHome dialysis therapiesHigh rateDepartment of HealthKidney injuryDiabetes mellitusDialysis patientsFacility patientsPeritoneal dialysisKidney diseaseReplacement therapyDialysis programRisk factorsSevere diseaseMedical conditionsSubstantial burdenPatients
2022
A randomized controlled pilot trial of anakinra for hemodialysis inflammation
Dember L, Hung A, Mehrotra R, Hsu J, Raj D, Charytan D, Mc Causland F, Regunathan-Shenk R, Landis J, Kimmel P, Kliger A, Himmelfarb J, Ikizler T, Consortium H. A randomized controlled pilot trial of anakinra for hemodialysis inflammation. Kidney International 2022, 102: 1178-1187. PMID: 35863559, PMCID: PMC9588554, DOI: 10.1016/j.kint.2022.06.022.Peer-Reviewed Original ResearchConceptsPatient-reported outcomesPlacebo groupAdverse eventsMedian decreaseHemodialysis patientsIL-6IL-1 receptor antagonistRate of adverse eventsEffect of anakinraPlacebo-controlled trialBaseline to weekAnti-cytokine therapyIL-1 inhibitionAssociated with morbidityAnakinra groupReceptor antagonistBetween-group differencesEfficacy outcomesAnakinraMaintenance hemodialysisRandomized controlled pilot trialChronic inflammationEvaluate safetyPlaceboIL-1Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease
Tuttle KR, Wong L, St. Peter W, Roberts G, Rangaswami J, Mottl A, Kliger A, Harris RC, Gee PO, Fowler K, Cherney D, Brosius FC, Argyropoulos C, Quaggin SE. Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease. Clinical Journal Of The American Society Of Nephrology 2022, 17: 1092-1103. PMID: 35649722, PMCID: PMC9269635, DOI: 10.2215/cjn.02980322.Commentaries, Editorials and LettersConceptsDiabetic kidney diseaseKidney disease careKidney diseaseHealth care systemDisease careKidney failureGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsPeptide-1 receptor agonistsAngiotensin-converting enzyme inhibitorBreakthrough therapiesMajor public health challengeHealth care system supportCare systemAngiotensin receptor blockersCotransporter 2 inhibitorsHalf of patientsPocket drug costsIndividual health care systemsPublic health challengeHealth care professionalsValue-based careEligible patientsMineralocorticoid antagonistsCardiovascular events
2021
Transforming the Care of Patients with Diabetic Kidney Disease
Brosius FC, Cherney D, Gee PO, Harris RC, Kliger A, Tuttle KR, Quaggin SE. Transforming the Care of Patients with Diabetic Kidney Disease. Clinical Journal Of The American Society Of Nephrology 2021, 16: 1590-1600. PMID: 34103350, PMCID: PMC8499007, DOI: 10.2215/cjn.18641120.Commentaries, Editorials and LettersConceptsRenin-angiotensin system inhibitorsDiabetic kidney diseaseIrbesartan Diabetic Nephropathy TrialCare of patientsKidney diseaseSystem inhibitorsNew therapiesAngiotensin II Antagonist Losartan (RENAAL) trialAngiotensin II type 1 receptor blockerDiabetic kidney disease progressionType 1 receptor blockerCardiovascular protective therapiesReduction of EndpointsKidney disease progressionKidney protective effectsRenin-angiotensin systemDiabetic Nephropathy TrialRisk of deathHigh residual riskHealth care providersPowerful new therapiesNephropathy TrialReceptor blockersDevastating complicationAntihypertensive agentsSARS-CoV-2 Antibody Dynamics in Chronic Hemodialysis Patients
Thwin O, Grobe N, Ye X, Preciado P, Silva L, Cherif A, Wang Y, Kshirsagar A, Kliger A, Finkelstein F, Kotanko P. SARS-CoV-2 Antibody Dynamics in Chronic Hemodialysis Patients. Journal Of The American Society Of Nephrology 2021, 32: 770-770. DOI: 10.1681/asn.20213210s1770b.Peer-Reviewed Original ResearchThe Microbiome and p-Inulin in Hemodialysis: A Feasibility Study.
Raj D, Sohn M, Charytan D, Himmelfarb J, Ikizler T, Mehrotra R, Ramezani A, Regunathan-Shenk R, Hsu J, Landis J, Li H, Kimmel P, Kliger A, Dember L. The Microbiome and p-Inulin in Hemodialysis: A Feasibility Study. Kidney360 2021, 2: 445-455. PMID: 35369018, PMCID: PMC8786005, DOI: 10.34067/kid.0006132020.Peer-Reviewed Original ResearchConceptsGut microbiomeStool samplesMicrobiome compositionMetabolomic profilesCLINICAL TRIAL REGISTRY NAMEWeighted UniFrac distancesStudy of patientsTRIAL REGISTRY NAMEUniFrac distancesMicrobiome diversityPretreatment to post-treatmentMaintenance hemodialysisUremic toxicityClinical trialsIntestinal microbiomeMicrobiomePost-treatmentREGISTRY NAMEGutPatientsHemodialysisMetabolome compositionFrequent sample collectionRegistration numberESKD
2020
Combination Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD (HIDE): A Randomized, Placebo-Controlled, Pilot Trial.
Charytan D, Hsu J, Mc Causland F, Waikar S, Ikizler T, Raj D, Landis J, Mehrotra R, Williams M, DiCarli M, Skali H, Kimmel P, Kliger A, Dember L, Himmelfarb J, Anderson A, Hung A, Sharma S, Weiner D. Combination Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD (HIDE): A Randomized, Placebo-Controlled, Pilot Trial. Kidney360 2020, 1: 1380-1389. PMID: 35372900, PMCID: PMC8815530, DOI: 10.34067/kid.0004342020.Peer-Reviewed Original ResearchConceptsIsosorbide dinitrateCoronary flow reserveAdverse eventsMaintenance HDMitral annular e' velocityDouble-blind pilot trialFlow reserveRecurrent intradialytic hypotensionRandomized to placeboMaximum tolerated doseTissue Doppler echocardiographyParticipants discontinued therapyGastrointestinal side effectsDetect between-group differencesPilot trialIntra-dialytic hypotensionPlacebo-ControlledPositron emission tomographyDose escalationHeart failure mortalityDose reductionStudy medicationTolerated dosePlacebo groupCombination therapy
2012
The Authors Reply
Rocco M, Kliger A. The Authors Reply. Kidney International 2012, 82: 115. DOI: 10.1038/ki.2012.96.Commentaries, Editorials and Letters
2011
The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial.
Rocco MV, Lockridge RS, Beck GJ, Eggers PW, Gassman JJ, Greene T, Larive B, Chan CT, Chertow GM, Copland M, Hoy CD, Lindsay RM, Levin NW, Ornt DB, Pierratos A, Pipkin MF, Rajagopalan S, Stokes JB, Unruh ML, Star RA, Kliger AS, Kliger A, Eggers P, Briggs J, Hostetter T, Narva A, Star R, Augustine B, Mohr P, Beck G, Fu Z, Gassman J, Greene T, Daugirdas J, Hunsicker L, Larive B, Li M, Mackrell J, Wiggins K, Sherer S, Weiss B, Rajagopalan S, Sanz J, Dellagrottaglie S, Kariisa M, Tran T, West J, Unruh M, Keene R, Schlarb J, Chan C, McGrath-Chong M, Frome R, Higgins H, Ke S, Mandaci O, Owens C, Snell C, Eknoyan G, Appel L, Cheung A, Derse A, Kramer C, Geller N, Grimm R, Henderson L, Prichard S, Roecker E, Rocco M, Miller B, Riley J, Schuessler R, Lockridge R, Pipkin M, Peterson C, Hoy C, Fensterer A, Steigerwald D, Stokes J, Somers D, Hilkin A, Lilli K, Wallace W, Franzwa B, Waterman E, Chan C, McGrath-Chong M, Copland M, Levin A, Sioson L, Cabezon E, Kwan S, Roger D, Lindsay R, Suri R, Champagne J, Bullas R, Garg A, Mazzorato A, Spanner E, Rocco M, Burkart J, Moossavi S, Mauck V, Kaufman T, Pierratos A, Chan W, Regozo K, Kwok S. The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. Kidney International 2011, 80: 1080-91. PMID: 21775973, PMCID: PMC3569086, DOI: 10.1038/ki.2011.213.Peer-Reviewed Original Research
2010
In-Center Hemodialysis Six Times per Week versus Three Times per Week
Chertow G, Levin N, Beck G, Depner T, Eggers P, Gassman J, Gorodetskaya I, Greene T, James S, Larive B, Lindsay R, Mehta R, Miller B, Ornt D, Rajagopalan S, Rastogi A, Rocco M, Schiller B, Sergeyeva O, Schulman G, Ting G, Unruh M, Star R, Kliger A. In-Center Hemodialysis Six Times per Week versus Three Times per Week. New England Journal Of Medicine 2010, 363: 2287-2300. PMID: 21091062, PMCID: PMC3042140, DOI: 10.1056/nejmoa1001593.Peer-Reviewed Original ResearchConceptsLeft ventricular massPhysical health composite scoresFrequent hemodialysisComposite outcomeVascular accessVentricular massSelf-reported depressionConventional hemodialysisCardiac magnetic resonance imagingConventional hemodialysis groupErythropoiesis-stimulating agentsRate of hospitalizationSerum albumin concentrationComposite scoreSelf-reported physical healthCognitive performanceMagnetic resonance imagingMaintenance hemodialysisSecondary outcomesBlood pressureLaboratory markersCenter hemodialysisClinical trialsMineral metabolismHealth SurveyChapter 25 Frequent Hemodialysis Physiological, Epidemiological, and Practical Aspects
Suri R, Kliger A. Chapter 25 Frequent Hemodialysis Physiological, Epidemiological, and Practical Aspects. 2010, 370-384. DOI: 10.1016/b978-1-4377-0987-2.00025-x.Chapters
2008
Correspondence: This letter was referred to the authors of the article in question who offer the following reply:
Kliger A, Gutman R. Correspondence: This letter was referred to the authors of the article in question who offer the following reply:. Seminars In Dialysis 2008, 21: 114-114. DOI: 10.1111/j.1525-139x.2007.00376.x.Commentaries, Editorials and Letters
2007
Will Innovations in Dialysis Improve Dialysis Care?
Kliger A, Gellens M. Will Innovations in Dialysis Improve Dialysis Care? Advances In Kidney Disease And Health 2007, 14: 229-230. DOI: 10.1053/j.ackd.2007.03.010.Peer-Reviewed Original Research
2001
PARAMETERS OF HIGH BONE-TURNOVER PREDICT BONE LOSS IN RENAL TRANSPLANT PATIENTS: A LONGITUDINAL STUDY1,2
Cruz D, Wysolmerski J, Brickel H, Gundberg C, Simpson C, Mitnick M, Kliger A, Lorber M, Basadonna G, Friedman A, Insogna K, Bia M. PARAMETERS OF HIGH BONE-TURNOVER PREDICT BONE LOSS IN RENAL TRANSPLANT PATIENTS: A LONGITUDINAL STUDY1,2. Transplantation 2001, 72: 83-88. PMID: 11468539, DOI: 10.1097/00007890-200107150-00017.Peer-Reviewed Original ResearchConceptsBone mineral densityPosttransplant bone lossRenal transplant recipientsLong-term renal transplant recipientsDual-energy X-ray absorptiometryRenal transplant patientsBone lossTransplant recipientsBone resorptionBiochemical markersTransplant patientsLumbar spineLong-term renal transplant patientsEnergy X-ray absorptiometryAccelerated bone resorptionElevated urinary levelsUse of cyclosporineElevated biochemical markersPrevious cross-sectional studiesCross-sectional studyX-ray absorptiometryStable bone massPostrenal transplantationAntiresorptive therapyKidney transplantationIdentification and treatment of depression in a cohort of patients maintained on chronic peritoneal dialysis
Wuerth D, Finkelstein S, Ciarcia J, Peterson R, Kliger A, Finkelstein F. Identification and treatment of depression in a cohort of patients maintained on chronic peritoneal dialysis. American Journal Of Kidney Diseases 2001, 37: 1011-1017. PMID: 11325684, DOI: 10.1016/s0272-6386(05)80018-6.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseChronic peritoneal dialysisBeck Depression InventoryAntidepressant medicationClinical depressionPsychiatric interviewerPeritoneal dialysisBDI scoresFurther evaluationMortality of patientsCohort of patientsHamilton Depression ScaleTreatment of depressionSelf-administered questionnaireRenal diseasePatient populationDepression ScaleLarge cohortPsychiatric interviewPatientsPossible therapyMedicationsDepression InventoryPilot studyTherapy